Aerie Pharmaceuticals has begun dosing in a phase 2 clinical trial of AR-1105, its dexamethasone intravitreal implant for patients with macular edema due to retinal vein occlusion.
Forty-five patients will be enrolled in the phase 2 study, which will be conducted at 20 U.S. centers, according to a press release. Safety, tolerability and efficacy of AR-1105 will be evaluated.
“This is a proof of concept study for AR-1105 and for the retina portfolio we are building based on two enabling technologies, the bioerodible polymers we are developing with DSM [Biomedical] (Read more...)
Uncategorized